register

Medical

First Australian study on cardiovascular impact of COVID-19 at The Alfred

Health Industry Hub | September 13, 2020 |

Medical News: While some international evidence suggests the infectious virus can leave behind cardiac scarring, cardiologists and respiratory physicians are working together to explore whether unexplained breathlessness may be the first sign of trouble.

The Alfred’s director of cardiology Professor David Kaye, and cardiologist Dr Shane Nanayakkara, have spent years studying pressure levels inside the hearts of patients as part of research into a condition known as heart failure with preserved ejection fraction (HFpEF).

In HFpEF, the heart muscle becomes stiff and doesn’t fill properly, leading to increased pressure and shortness of breath.  Together with respiratory physician Professor Trevor Williams, Professor Kaye and his team are looking for the same signs of damage in those who have had COVID-19.

“While the international evidence has been mixed, it’s possible that some patients sustain cardiac damage from COVID-19 infection,” Prof Kaye said.

“Similar to HFpEF, one of the ways of we can measure changes in the heart is to perform catheter testing during exercise.”

After inserting a slim catheter into the body via a patient’s arm, they are asked to lie on a bed that has bike pedals attached. Dr Nanayakkara said the team then observes the pressures inside the heart as the patient exercises.

“If the pressures go up abnormally, that’s a warning sign, and then we can explore further and, hopefully, offer treatment,” Dr Nanayakkara said.

“We still have a lot to learn about the mark COVID can leave on the heart, but we encourage anyone who experiences unexplained and prolonged breathlessness after the virus to ask their GP for a referral to come and see us in the Heart Centre at The Alfred.”


Medical

NSW Health to settle class action

NSW Health to settle ‘largest’ class action

Health Industry Hub | April 29, 2024 |

A class action alleging NSW Health underpaid clinicians has settled after the department agreed to a payout of nearly a […]

More


News & Trends - Pharmaceuticals

Lilly's first-in-class therapy PBS listed for early breast cancer after 15-year gap

Lilly’s first-in-class therapy PBS listed for early breast cancer after 15-year gap

Health Industry Hub | April 29, 2024 |

Pharma News: Australians diagnosed with early-stage breast cancer, particularly those at high risk of recurrence, will gain access to the […]

More


News & Trends - Pharmaceuticals

AstraZeneza secures four PBAC nods in oncology, diabetes, kidney and rare diseases

AstraZeneza secures four PBAC nods in oncology, diabetes, kidney and rare diseases

Health Industry Hub | April 29, 2024 |

Pharma News: AstraZeneca has scored four positive Pharmaceutical Benefits Advisory Committee (PBAC) recommendations following the March meeting. These recommendations, spanning […]

More


News & Trends - Pharmaceuticals

PBAC recommendation to reshape prescribing in heart failure

PBAC recommendation to reshape prescribing in heart failure

Health Industry Hub | April 29, 2024 |

Pharma News: Aligned with the government’s Scope of Practice Review, the Pharmaceutical Benefits Advisory Committee (PBAC) has made a practice-changing […]

More


This content is copyright protected. Please subscribe to gain access.